Claus-Christoph Steffens

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +10

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller et al. · The Lancet Oncology · 2015 · 251 citations

Medicine, Oncology, Pharmacology +12

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study

Claus-Christoph Steffens, Corinna Elender, Ulrich Hutzschenreuter et al. · Lung Cancer · 2019 · 49 citations · Full text

Medicine, Oncology, Chemotherapy +12

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

R. Charles Coombes, Holly Tovey, Lucy Kilburn et al. · JAMA Oncology · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +15